SAVE MONEY ON TRAVEL DEALS

Children's Hospital Boston researchers said the first oral, broad-spectrum angiogenesis inhibitor they created shows promising anti-cancer results in mice.

Since it's a non-toxic oral medication, the scientists say the drug -- called Lodamin -- might be useful as a preventive therapy for patients at high risk for cancer or as a chronic maintenance therapy for a variety of cancers, preventing tumors from forming or recurring by blocking the growth of blood vessels to feed them.

Lodamin may also be useful in other diseases that involve aberrant blood-vessel growth, such as age-related macular degeneration and arthritis, they said.

Developed by Ofra Benny and the late Dr. Judah Folkman, Lodamin is a slow-release reformulation of TNP-470, a drug developed nearly two decades ago by Dr. Donald Ingber. It was one of the first angiogenesis inhibitors to undergo clinical testing.

The scientists said Lodamin appears to retain TNP-470's potency and broad spectrum of activity, but with no detectable neurotoxicity and greatly enhanced oral availability.

The research is reported online in the journal Nature Biotechnology.

 BREAKING STORIES

Ballesteros says he has brain tumor

Bollywood's Bachchan hospitalized

Official: Russia has no melamine victims

Plastic surgery makes advances in wartime

New law puts mental, physical ills on par

Cervical cancer shot gains acceptance

Study: Ginkgo can prevent stroke damage

WHO probes deadly mystery illness

Claim: Magic Johnson 'faked' AIDS

Exercise intervention helps with arthritis

WHO: Mental health stigma unfair

Bird flu survival tied to hands-on therapy

TV star to wed after getting cancer news

NSAIDs linked to lower breast cancer risk

Kids' asthma diagnosis can be a challenge

Herb may help curb bad breath

New procedure to correct sagging breasts

Why pizza may cause women pain, urination

Cocoa powder high in anti-oxidants

Genetic code of malaria parasite sequenced